Continuous Improvement and the Expansion of Quality ... - NCQA

Recommendations

Info

T H E S TAT E o f H E A l T H C A R E Q U A l I T y 2 0 1 1 • A P P E N D I C E S APPENDIx 10: HMoS VS. PPoS, CoMMERCIAl PlANS HEdIs EffECtIvEnEss of CarE MEasurEs HMos vs. PPos: CoMMErCIal avEragEs—2010 MEASURE HMo PPo DIffERENCE safety and Potential Waste Imaging Studies for low back Pain 74.2 73.3 -0.9 Avoidance of Antibiotic Treatment in Adults With Acute bronchitis 22.5 21.3 -1.2 Ambulatory Care—ED Visits per 1,000 Member Months 187.4 174 -13.4 Wellness and Prevention Medical Assistance With Smoking and Tobacco Use Cessation— Advising Smokers and Tobacco Users to Quit Medical Assistance With Smoking and Tobacco Use Cessation— Discussing Cessation Strategies Medical Assistance With Smoking and Tobacco Use Cessation— Discussing Cessation Medications 76.7 71.7 -5.0 45.0 39.0 -6.0 52.4 47.2 -5.1 flu Shots for Adults 52.5 51.6 -0.9 breast Cancer Screening 70.8 67.0 -3.8 Cervical Cancer Screening 77.0 74.5 -2.4 Chlamydia Screening in Women—16–20 years 40.8 38.1 -2.7 Chlamydia Screening in Women—21–24 years 45.7 41.9 -3.8 Chlamydia Screening in Women—Total Rate 43.1 40.0 -3.1 Chronic disease Management Persistence of beta-blocker Treatment After a Heart Attack 75.5 71.3 -4.2 Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis 87.7 87.0 -0.7 Use of Appropriate Medications for People With Asthma—5–11 years 96.7 97.0 0.4 Use of Appropriate Medications for People With Asthma—12–50 years 91.8 91.8 0.0 Use of Appropriate Medications for People With Asthma—overall Rate 92.9 93.0 0.2 Use of Spirometry Testing in the Assessment and Diagnosis of CoPD 41.7 40.2 -1.5 Pharmacotherapy Management of CoPD—bronchodilators 77.8 73.5 -4.3 Pharmacotherapy Management of CoPD—Systemic Corticosteroids 69.8 66.2 -3.7 Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARbs 81.6 78.4 -3.2 Annual Monitoring for Patients on Persistent Medications—Anticonvulsants 60.4 57.9 -2.5 Annual Monitoring for Patients on Persistent Medications—Digoxin 84.6 79.1 -5.5 Annual Monitoring for Patients on Persistent Medications—Diuretics 81.0 78.1 -2.9 Annual Monitoring for Patients on Persistent Medications—Combined 80.9 77.8 -3.1 Antidepressant Medication Management—Acute Phase 64.7 64.3 -0.4 Antidepressant Medication Management—Continuation Phase 48.3 48.1 -0.3 follow-Up After Hospitalization for Mental Illness—Within 7 Days Post-Discharge 59.7 54.2 -5.6 follow-Up After Hospitalization for Mental Illness—Within 30 Days Post-Discharge 77.4 74.1 -3.2 Alcohol and other Drug Dependence Treatment—Engagement 15.6 16.0 0.3 165
166 N AT I o N A l C o M M I T T E E f o R Q U A l I T y A S S U R A N C E HEdIs EffECtIvEnEss of CarE MEasurEs HMos vs. PPos: CoMMErCIal avEragEs—2010 MEASURE HMo PPo DIffERENCE Alcohol and other Drug Dependence Treatment—Initiation 42.7 40.8 -1.9 Measures targeted toward Children and adolescents Appropriate Testing for Children With Pharyngitis 77.6 76.6 -0.9 Appropriate Testing for Children With Upper Respiratory Infection 85.1 83.7 -1.4 follow-Up Care for Children Prescribed ADHD Medication—Initiation 38.8 38.1 -0.7 follow-Up Care for Children Prescribed ADHD Medication—Continuation 43.4 43.3 -0.1 Well-Child Visits: Ages 0–15 Months—No Well-Child Visits 1.6 2.9 1.4 Well-Child Visits: Ages 0–15 Months—one Well-Child Visit 1.1 1.5 0.5 Well-Child Visits: Ages 0–15 Months—Two Well-Child Visits 1.3 1.7 0.4 Well-Child Visits: Ages 0–15 Months—Three Well-Child Visits 2.2 2.7 0.5 Well-Child Visits: Ages 0–15 Months—four Well-Child Visits 4.9 5.3 0.4 Well-Child Visits: Ages 0–15 Months—five Well-Child Visits 12.8 13.0 0.2 Well-Child Visits: Ages 0–15 Months—Six or More Well-Child Visits 76.3 72.8 -3.6 Well-Child Visits: Ages 3–6 years—one or More Well-Child Visits 71.6 67.8 -3.8 Adolescent Well-Care Visits—At least one Comprehensive Well-Care Visit 42.7 39.2 -3.5 Children and Adolescents’ Access to Primary Care Practitioners—Children 12–24 Months 97.5 96.9 -0.6 Children and Adolescents’ Access to Primary Care Practitioners—Children 25 Months–6 years 91.2 89.1 -2.1 Children and Adolescents’ Access to Primary Care Practitioners—Children 7–11 years 91.6 89.4 -2.2 Children and Adolescents’ Access to Primary Care Practitioners—Adolescents 12–19 years 89.2 86.8 -2.4 *Lower rates signify better performance.
Page 1 and 2:
Continuous Improvement and the Expa
Page 3 and 4:
2 This Report and the data containe
Page 5 and 6:
4 N AT I o N A l C o M M I T T E E
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
top 10 and bottom 10 states “loca
Page 15 and 16:
Page 17 and 18:
16 this measure has shown steady ga
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
24 HEDIS MEASURES of CARE about HEd
Page 27 and 28:
S A f E T y A N D P o T E N T I A l
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
W E l l N E S S A N D P R E V E N T
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
C H R o N I C D I S E A S E M A N A
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
M E A S U R E S T A R G E T E D A T
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116: M E A S U R E S T A R G E T E D A T
Page 121 and 122: C o N S U M E R A N D P A T I E N T
Page 129 and 130: 128 N AT I o N A l C o M M I T T E
Page 131 and 132: 130 APPENDIx 1: HEDIS EffECTIVENESS
Page 135 and 136: 134 APPENDIx 2: HEDIS EffECTIVENESS
Page 143 and 144: 142 APPENDIx 4b: ACCREDITED VS. NoN
Page 149 and 150: 148 APPENDIx 6A: ACCREDITED VS. NoN
Page 151 and 152: 150 APPENDIx 6b: ACCREDITED VS. NoN
Page 153 and 154: 152 APPENDIx 7A: PUblICly REPoRTING
Page 159 and 160: 158 APPENDIx 8: PUblICly REPoRTING
Page 165: 164 N AT I o N A l C o M M I T T E
Page 173 and 174: 172 MEASURE N AT I o N A l C o M M
Page 175 and 176: 174 APPENDIx 14b: VARIATIoN IN PlAN
Page 181 and 182: 180 APPENDIx 16A: VARIATIoN IN PlAN
Page 183 and 184: 182 APPENDIx 16b: VARIATIoN IN PlAN
Page 185 and 186: 184 REfERENCES N AT I o N A l C o M
Page 200 and 201: ACkNoWlEDGMENTS Health Plans The 20
show all

Continuous Improvement and the Expansion of Quality ... - NCQA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?